Literature DB >> 28598867

Pathophysiology of antenatal Bartter's syndrome.

Martin Kömhoff1, Kamel Laghmani.   

Abstract

PURPOSE OF REVIEW: Antenatal Bartter syndrome (aBS) is a heterogenous disease resulting from defective ion transport in the thick ascending limb of the loop of Henle. Novel insights into the pathophysiology, as well as the recent identification of a novel genetic cause of aBS, merit an update on this topic. RECENT
FINDINGS: In aBS, severe salt losing is further aggravated by defective salt sensing in the macula densa, where a reduced tubular salt concentration is perceived and glomerular filtration is increased instead of decreased. As patients with aBS come of age, there is an increased incidence of proteinuria and impaired renal function.Moreover, we recently reported a new form of aBS. Indeed, we described a series of nine families in whom pregnancies with male fetuses where complicated by acute polyhydramnios, preterm delivery and with severe but transient polyuria. We identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.
SUMMARY: Genetic studies revealed the complexity of ion transport in the thick ascending limb of the loop of Henle and will help to clarify the pathophysiology, which is essential to design new therapies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28598867     DOI: 10.1097/MNH.0000000000000346

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  9 in total

Review 1.  Salt-Losing Tubulopathies in Children: What's New, What's Controversial?

Authors:  Robert Kleta; Detlef Bockenhauer
Journal:  J Am Soc Nephrol       Date:  2017-12-13       Impact factor: 10.121

Review 2.  Genetic diagnosis and treatment of hereditary renal tubular disease with hypokalemia and alkalosis.

Authors:  Wenkai Guo; Pengcheng Ji; Yuansheng Xie
Journal:  J Nephrol       Date:  2022-08-22       Impact factor: 4.393

3.  Adjunctive acetazolamide therapy for the treatment of Bartter syndrome.

Authors:  Mojgan Mazaheri; Farahnak Assadi; Simin Sadeghi-Bojd
Journal:  Int Urol Nephrol       Date:  2019-12-09       Impact factor: 2.370

Review 4.  Novel Aspects of Renal Magnesium Homeostasis.

Authors:  Paula Giménez-Mascarell; Carlotta Else Schirrmacher; Luis Alfonso Martínez-Cruz; Dominik Müller
Journal:  Front Pediatr       Date:  2018-04-09       Impact factor: 3.418

5.  Differential Effects of STCH and Stress-Inducible Hsp70 on the Stability and Maturation of NKCC2.

Authors:  Dalal Bakhos-Douaihy; Elie Seaayfan; Sylvie Demaretz; Martin Komhoff; Kamel Laghmani
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

6.  Golgi Alpha1,2-Mannosidase IA Promotes Efficient Endoplasmic Reticulum-Associated Degradation of NKCC2.

Authors:  Sylvie Demaretz; Elie Seaayfan; Dalal Bakhos-Douaihy; Nadia Frachon; Martin Kömhoff; Kamel Laghmani
Journal:  Cells       Date:  2021-12-29       Impact factor: 6.600

7.  Late-Onset Bartter Syndrome Type II Due to a Novel Compound Heterozygous Mutation in KCNJ1 Gene: A Case Report and Literature Review.

Authors:  Mi Tian; Hui Peng; Xin Bi; Yan-Qiu Wang; Yong-Zhe Zhang; Yan Wu; Bei-Ru Zhang
Journal:  Front Med (Lausanne)       Date:  2022-04-07

8.  Balancing Benefits and Risks of Indomethacin in the Management of Antenatal Bartter Syndrome: A Case Report.

Authors:  Omar Ala' Alajjuri; Mayar Essam Samaha; Ulrich Honemeyer; Ghada Mohammed; Noha A Mousa
Journal:  Front Med (Lausanne)       Date:  2022-06-29

Review 9.  Bartter's syndrome: clinical findings, genetic causes and therapeutic approach.

Authors:  Flavia Cristina Carvalho Mrad; Sílvia Bouissou Morais Soares; Luiz Alberto Wanderley de Menezes Silva; Pedro Versiani Dos Anjos Menezes; Ana Cristina Simões-E-Silva
Journal:  World J Pediatr       Date:  2020-06-01       Impact factor: 2.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.